User login
Key clinical point: HCC patients who underwent hepatic resection had significantly higher rates of overall survival and recurrence-free survival compared to those who underwent percutaneous ablation.
Major finding: Overall survival at 1, 3, and 5 years was 97.6%, 83.6%, and 71.5%, respectively, for the hepatic resection patients, vs 89.4%, 58.5%, and 48.8%, respectively, for the percutaneous ablation patients (P = 0.032). Recurrence-free survival at these time points was 77.6%, 47.9%, and 42.6%, respectively, for the hepatic resection group, and 40.5%, 23.2%, and 15.4%, respectively, for the percutaneous ablation group (P = 0.010).
Study details: The data come from a retrospective study of 67 adults with resectable caudate HCC within Milan criteria at three centers; 46 underwent hepatic resection and 21 underwent percutaneous ablation.
Disclosures: The study was supported by the National Science Fund for Distinguished Young Scholars, the National Natural Science Foundation of China, and the Natural Science Foundation of Guangdong, China.
Source: Xie W et al. J Gastrointest Surg. 2021 Sep 7. doi: 10.1007/s11605-021-05111-0.
Key clinical point: HCC patients who underwent hepatic resection had significantly higher rates of overall survival and recurrence-free survival compared to those who underwent percutaneous ablation.
Major finding: Overall survival at 1, 3, and 5 years was 97.6%, 83.6%, and 71.5%, respectively, for the hepatic resection patients, vs 89.4%, 58.5%, and 48.8%, respectively, for the percutaneous ablation patients (P = 0.032). Recurrence-free survival at these time points was 77.6%, 47.9%, and 42.6%, respectively, for the hepatic resection group, and 40.5%, 23.2%, and 15.4%, respectively, for the percutaneous ablation group (P = 0.010).
Study details: The data come from a retrospective study of 67 adults with resectable caudate HCC within Milan criteria at three centers; 46 underwent hepatic resection and 21 underwent percutaneous ablation.
Disclosures: The study was supported by the National Science Fund for Distinguished Young Scholars, the National Natural Science Foundation of China, and the Natural Science Foundation of Guangdong, China.
Source: Xie W et al. J Gastrointest Surg. 2021 Sep 7. doi: 10.1007/s11605-021-05111-0.
Key clinical point: HCC patients who underwent hepatic resection had significantly higher rates of overall survival and recurrence-free survival compared to those who underwent percutaneous ablation.
Major finding: Overall survival at 1, 3, and 5 years was 97.6%, 83.6%, and 71.5%, respectively, for the hepatic resection patients, vs 89.4%, 58.5%, and 48.8%, respectively, for the percutaneous ablation patients (P = 0.032). Recurrence-free survival at these time points was 77.6%, 47.9%, and 42.6%, respectively, for the hepatic resection group, and 40.5%, 23.2%, and 15.4%, respectively, for the percutaneous ablation group (P = 0.010).
Study details: The data come from a retrospective study of 67 adults with resectable caudate HCC within Milan criteria at three centers; 46 underwent hepatic resection and 21 underwent percutaneous ablation.
Disclosures: The study was supported by the National Science Fund for Distinguished Young Scholars, the National Natural Science Foundation of China, and the Natural Science Foundation of Guangdong, China.
Source: Xie W et al. J Gastrointest Surg. 2021 Sep 7. doi: 10.1007/s11605-021-05111-0.